Brokers Offer Predictions for GSK’s Q4 Earnings (NYSE:GSK)

GSK plc (NYSE:GSK) – Research analysts at Zacks Research decreased their Q4 2024 EPS estimates for shares of GSK in a research note issued on Tuesday, November 19th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $0.63 per share for the quarter, down from their prior estimate of $0.76. The consensus estimate for GSK’s current full-year earnings is $4.03 per share. Zacks Research also issued estimates for GSK’s Q4 2025 earnings at $0.84 EPS, FY2025 earnings at $4.34 EPS, Q2 2026 earnings at $1.13 EPS and FY2026 earnings at $4.90 EPS.

GSK has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft downgraded shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Barclays upgraded shares of GSK to a “hold” rating in a report on Tuesday, August 27th. Jefferies Financial Group downgraded shares of GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim downgraded shares of GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, Argus upgraded shares of GSK to a “strong-buy” rating in a report on Wednesday, August 7th. Seven analysts have rated the stock with a hold rating and three have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Stock Performance

Shares of NYSE GSK opened at $33.67 on Thursday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a market cap of $69.79 billion, a P/E ratio of 21.87, a P/E/G ratio of 1.29 and a beta of 0.66. The firm’s fifty day moving average is $38.27 and its two-hundred day moving average is $40.44. GSK has a 52-week low of $32.83 and a 52-week high of $45.92.

Institutional Investors Weigh In On GSK

A number of institutional investors have recently made changes to their positions in GSK. Second Line Capital LLC purchased a new position in GSK in the third quarter worth approximately $245,000. Rehmann Capital Advisory Group lifted its stake in GSK by 6.3% in the third quarter. Rehmann Capital Advisory Group now owns 5,608 shares of the pharmaceutical company’s stock worth $232,000 after acquiring an additional 332 shares during the last quarter. TD Private Client Wealth LLC lifted its stake in GSK by 36.9% in the third quarter. TD Private Client Wealth LLC now owns 12,422 shares of the pharmaceutical company’s stock worth $508,000 after acquiring an additional 3,346 shares during the last quarter. Sunbelt Securities Inc. lifted its stake in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the last quarter. Finally, Continuum Advisory LLC lifted its stake in GSK by 4.8% in the third quarter. Continuum Advisory LLC now owns 10,599 shares of the pharmaceutical company’s stock worth $433,000 after acquiring an additional 487 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other GSK news, major shareholder Plc Gsk purchased 2,791,930 shares of the firm’s stock in a transaction dated Friday, September 27th. The shares were purchased at an average cost of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now owns 16,775,691 shares in the company, valued at approximately $134,205,528. This represents a 19.97 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. 10.00% of the stock is currently owned by insiders.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be issued a dividend of $0.3928 per share. The ex-dividend date is Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.67%. GSK’s dividend payout ratio is 99.35%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.